CCO Treatment Updates
Proceedings of the 17th International Prostate Cancer Update Meeting
Epidemiology, Screening, Prevention, and Biomarkers
|
Module 1 of 6
|
- Per-Anders Abrahamsson, MD, PhD
|
|
|
 Per-Anders Abrahamsson, MD, PhD, reviews current data on the epidemiology, screening, prevention, and biomarkers associated with prostate cancer presented at the 2007 International Prostate Cancer Update meeting held in Vail, Colorado. Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe prognostic factors regarding life expectancy in patients with prostate cancer
- Summarize the use of prostate-specific antigen kinetics to predict risk of prostate cancer
- Discuss issues in prostate cancer screening
|
Complementary/Alternative Medicine and Testosterone Replacement Therapy
|
Module 2 of 6
|
|
|
|
Mark A. Moyad, MD, MPH, reviews current data on the use of complementary and alternative therapies in the treatment of high-risk patients with prostate cancer, which were presented at the 17th International Prostate Cancer Update meeting in Vail, Colorado. Learning Objectives
Upon completion of this activity, participants should be able to:
- Summarize issues in the use of testosterone replacement therapy in high-risk patients with prostate cancer
- Discuss the use of vitamin supplements in the treatment of patients with prostate cancer
- Review optimal biopsy strategies in the treatment of prostate cancer
|
Treatment of Localized Disease
|
Module 3 of 6
|
|
|
|
Mack Roach III, MD, reviews current data on the treatment of localized disease presented at the 2007 International Prostate Cancer Update meeting held in Vail, Colorado. Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss current data on screening and imaging modalities for prostate cancer
- Summarize therapeutic approaches, including surgery and radiotherapy, for localized disease
- Define status of clinical trials for short- and long-term hormonal therapy
|
Treatment of Advanced or Hormone-Refractory Disease
|
Module 4 of 6
|
- Nicholas J. Vogelzang, MD
|
|
|
Nicholas J. Vogelzang, MD, reviews data on treating advanced or hormone-refractory prostate cancer presented at the 2007 International Prostate Cancer Update meeting held in Vail, Colorado. Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss first- and second-line treatment strategies for advanced or hormone-refractory prostate cancer patients
- Describe immunotherapy approaches for treating advanced prostate cancer patients
- Summarize clinical trial data on new hormonal agents for treating advanced or hormone-refractory patients
|
Risk Stratification and Management of High-Risk Patients
|
Module 5 of 6
|
|
|
|
Daniel P. Petrylak, MD, reviews current data on risk stratification and clinical management of high-risk patients presented at the 17th International Prostate Cancer Update meeting held in Vail, Colorado. Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss controversial issues in the management of high-risk patients
- Summarize the use of radiation therapy and hormone therapy in the treatment of high-risk patients with prostate cancer
- Review the use of prognostic factors, including novel diagnostic and prognostic techniques, in prostate cancer treatment
|
New Techniques and Management Options for Disease and Treatment Complications
|
Module 6 of 6
|
|
|
|
James A. Eastham, MD, reviews new techniques and management options for disease and treatment-related complications presented at the 2007 International Prostate Cancer Update held in Vail, Colorado. Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss current data on androgen deprivation therapy for the treatment of prostate cancer
- Describe the use of transrectal ultrasound in the diagnosis of patients with prostate cancer
- Summarize the effect of surgeon experience on outcomes following radical prostatectomy
|
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|